A phase I study of MEK inhibitor MEK162 (ARRY-438162) in patients with biliary tract cancer.

被引：29
作者：
Finn, Richard S.
Javle, Milind M.
Tan, Benjamin R.
Weekes, Colin D.
Bendell, Johanna C.
Patnaik, Amita
Khan, Gazala Naaz
Laheru, Dan
Anderson, Lisa
Christy-Bittel, Janna Lynn
Barrett, Emma
Guthrie, Kari
Litwiler, Kevin S.
Bekaii-Saab, Tanios S.
机构：
[1] Univ Calif Los Angeles, Los Angeles, CA USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] Washington Univ, Sch Med, St Louis, MO 63110 USA
[4] Univ Colorado, Canc Ctr, Aurora, CO USA
[5] Sarah Cannon Res Inst, Nashville, TN USA
[6] South Texas Accelerated Res Therapeut START, Ctr Canc Care, San Antonio, TX USA
[7] Univ Michigan Hosp, Ann Arbor, MI USA
[8] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[9] Array BioPharma, Boulder, CO USA
[10] Ohio State Univ, Med Ctr, Columbus, OH USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 04期
关键词：
D O I：
10.1200/jco.2012.30.4_suppl.220
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
220
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Clinical aspects of a phase I study of PD-0325901, a selective oral MEK inhibitor, in patients with advanced cancer
    LoRusso, Patricia A.
    Krishnamurthi, Smitha S.
    Rinehart, John J.
    Nabell, Lisle M.
    Croghan, Gary A.
    Chapman, Paul B.
    Selaru, Paulina
    Kim, Sinil
    Ricart, Alejandro D.
    Wilner, Keith D.
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3469S - 3470S
  • [42] The development of the BRAF inhibitor encorafenib (LGX818) and mitogen-activated protein kinase kinase inhibitor binimetinib (MEK162) in patients with metastatic melanoma
    Dummer, R.
    Flaherty, K.
    Kefford, R.
    Ascierto, P. A.
    Moutouh-de Parseval, L.
    Wasserman, E.
    Schadendorf, D.
    BRITISH JOURNAL OF DERMATOLOGY, 2014, 171 : 67 - 68
  • [43] Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies
    LoRusso, PM
    Adjei, AA
    Varterasian, M
    Gadgeel, S
    Reid, J
    Mitchell, DY
    Hanson, L
    DeLuca, P
    Bruzek, L
    Piens, J
    Asbury, P
    Van Becelaere, K
    Herrera, R
    Sebolt-Leopold, J
    Meyer, MB
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (23) : 5281 - 5293
  • [44] Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma
    Anthony W. Tolcher
    Amita Patnaik
    Kyriakos P. Papadopoulos
    Drew W. Rasco
    Carlos R. Becerra
    Alicia J. Allred
    Keith Orford
    Gursel Aktan
    Geraldine Ferron-Brady
    Nageatte Ibrahim
    Jennifer Gauvin
    Monica Motwani
    Mark Cornfeld
    Cancer Chemotherapy and Pharmacology, 2015, 75 : 183 - 189
  • [45] Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma
    Tolcher, Anthony W.
    Patnaik, Amita
    Papadopoulos, Kyriakos P.
    Rasco, Drew W.
    Becerra, Carlos R.
    Allred, Alicia J.
    Orford, Keith
    Aktan, Gursel
    Ferron-Brady, Geraldine
    Ibrahim, Nageatte
    Gauvin, Jennifer
    Motwani, Monica
    Cornfeld, Mark
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 75 (01) : 183 - 189
  • [46] A phase 1b dose-escalation study of BYL719 plus binimetinib (MEK162) in patients with selected advanced solid tumors.
    Juric, Dejan
    Soria, Jean-Charles
    Sharma, Sunil
    Banerji, Udai
    Azaro, Analia
    Desai, Jayesh
    Ringeisen, Francois Philippe
    Kaag, Audrey
    Radhakrishnan, Rajkumar
    Hourcade-Potelleret, Florence
    Maacke, Heiko
    Ahnert, Jordi Rodon
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [47] MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study
    Ascierto, Paolo A.
    Schadendorf, Dirk
    Berking, Carola
    Agarwala, Sanjiv S.
    van Herpen, Carla M. L.
    Queirolo, Paola
    Blank, Christian U.
    Hauschild, Axel
    Beck, J. Thaddeus
    St-Pierre, Annie
    Niazi, Faiz
    Wandel, Simon
    Peters, Malte
    Zubel, Angela
    Dummer, Reinhard
    LANCET ONCOLOGY, 2013, 14 (03) : 249 - 256
  • [48] Enhanced antitumor effect of binimetinib in combination with capecitabine for biliary tract cancer patients with mutations in the RAS/RAF/MEK/ERK pathway: phase Ib study
    Kim, Jin Won
    Lee, Kyung-Hun
    Kim, Ji-Won
    Suh, Koung Jin
    Nam, Ah-Rong
    Bang, Ju-Hee
    Bang, Yung-Jue
    Oh, Do-Youn
    BRITISH JOURNAL OF CANCER, 2019, 121 (04) : 332 - 339
  • [49] A phase I study of binimetinib, a MEK inhibitor, in combination with pembrolizumab in patients with advanced non-small cell lung cancer (NSCLC)
    Theriau, Christopher F.
    Feng, Jamie
    Eng, Lawson
    Shepherd, Frances A.
    DeCarolis, Mary
    Glenns, Vivian
    Kulkarni, Swati
    VanderMeer, Rachel
    Zurawska-Fortin, Urszula
    Hao, Desiree
    Le, Lisa
    Wozniczka, Isabel
    Al-Kindy, Aida
    Xie, Danny
    Zhang, Tong
    Subramanian, Vasanth
    Stockley, Tracy
    Bradbury, Penelope A.
    Liu, Geoffrey
    Leighl, Natasha B.
    CANCER RESEARCH, 2023, 83 (08)
  • [50] Enhanced antitumor effect of binimetinib in combination with capecitabine for biliary tract cancer patients with mutations in the RAS/RAF/MEK/ERK pathway: phase Ib study
    Jin Won Kim
    Kyung-Hun Lee
    Ji-Won Kim
    Koung Jin Suh
    Ah-Rong Nam
    Ju-Hee Bang
    Yung-Jue Bang
    Do-Youn Oh
    British Journal of Cancer, 2019, 121 : 332 - 339
12345